First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b

NCT06517485 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

142

Enrollment

INDUSTRY

Sponsor class

Conditions

Platinum Resistant Ovarian Cancer
Non-Small Cell Adenocarcinoma

Interventions

DRUG: upifitamab rilsodotin

Sponsor

Mersana Therapeutics